This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities (19 October 2012)
| Read the full announcement in PDF format |
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, for Tresiba® and Ryzodeg® for the treatment of diabetes mellitus in adults.
Further information:
Media: | Investors: |
| Mike Rulis | Kasper Roseeuw Poulsen |
| Tel: (+45) 3079 3573 | Tel: (+45) 4442 4303 |
| mike@novonordisk.com | krop@novonordisk.com |
| Frank Daniel Mersebach | |
| Tel: (+45) 4442 0604 | |
| fdni@novonordisk.com | |
| Lars Borup Jacobsen | |
| Tel: (+45) 3075 3479 | |
| lbpj@novonordisk.com | |
| In North America: | |
| Ambre Morley | Jannick Lindegaard |
| Tel: (+1) 609 216 5240 | Tel: (+1) 609 786 4575 |
| abmo@novonordisk.com | jlis@novonordisk.com |
Company announcement No 66 / 2012
